StemRIM (4599) · RiskAppointment as Representative Director, Chairman and CSO
Dependence on founder Tamai Katsuhito (玉井 克人) for research and development and the management foundation
First written in FY2019. 1 of 3 entries say "Restated". Latest entry: FY2026.
3entries
8years
1from disclosures
How it moved
Same theme, other companies
Dependence on Key ExecutivesA theme 560 companies write about · 560 as a headwind · 0 as a tailwind
The whole theme swung hardest in 2026: 10 of 77 companies on the "Worse" side.
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 560 threads.Full recordFilings, disclosures and news, newest first
- FY2026Appointment as Representative Director, Chairman and CSOAnnual report
「September 2026 Representative Director, Chairman and CSO of the Company (current)」
Founder Tamai Katsuto (玉井 克人) became Representative Director, Chairman and CSO in September 2026. The change in title indicates that he continues to be involved in research and development and in the company's management foundation. - 2026-09-09RestatedChanges in Officers
「By having the founder join the core of management as Representative Director, we will further strengthen our commitment to the research and development of in vivo regenerative medicine and accelerate these efforts.」
The appointment of founder Tamai Katsuhito (玉井 克人) as Representative Director, Chairman and CSO established a structure in which he assumes a central role in research and development and management. This relates to the existing issue of dependence on the founder for research and development and the management foundation, but the canonical thread itself remains unchanged. - FY2019First statedAnnual report
「We believe that Tamai Katsuhito (玉井克人)'s continued involvement with the Company will remain essential. If his involvement becomes difficult for any reason, this could affect the Company's business and other operations.」
The founder explains that he occupies an important position in research and development, joint research with Osaka University, and the Company's management foundation.